Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Zimmer Holdings (NY:ZBH)

91.85 +0.74 (+0.81%)
Official Closing Price Updated: 7:00 PM EDT, Jun 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Zimmer Holdings

< Previous 1 2 3 4 5 6 7 8 9 Next >
What 7 Analyst Ratings Have To Say About Zimmer Biomet Holdings
Via Benzinga
Why Is Zimmer Biomet Stock Trading Lower Today?
Zimmer Biomet's Q4 2023 results, featuring 6.3% Y/Y net sales growth, $2.20 adjusted EPS, and a global restructuring plan for $200M cost savings. 
Via Benzinga
(ZBH) - Analyzing Zimmer Biomet Holdings's Short Interest
Via Benzinga
Earnings Scheduled For February 8, 2024
Companies Reporting Before The Bell • Ares Management (NYSE:ARES) is expected to report quarterly earnings at $1.09 per share on revenue of $864.54 million. 
Via Benzinga
Blackstone, Zimmer Biomet And A Membership Warehouse Retailer: CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Jason Snipe of Odyssey Capital Advisors said he likes Blackstone Inc. (NYSE: BX) here, despite the firm's 
Via Benzinga
Peering Into Zimmer Biomet Holdings's Recent Short Interest
Via Benzinga
Unveiling 10 Analyst Insights On Zimmer Biomet Holdings
Via Benzinga
Beyond The Numbers: 8 Analysts Discuss Zimmer Biomet Holdings Stock
Via Benzinga
(ZBH) - Analyzing Zimmer Biomet Holdings's Short Interest
Via Benzinga
Zimmer Biomet Holdings's Ex-Dividend Date Is Tuesday, Here's What You Need To Know
Via Benzinga
Hidden gems: 3 undervalued stocks with a unique competitive edge
Etsy, International Flavors & Fragrances and Zimmer Biomet are undervalued stocks with unique market advantages. Patient investors may find opportunities here. 
Via MarketBeat
Where Zimmer Biomet Holdings Stands With Analysts
Via Benzinga
Orthopedic Giant Zimmer Biomet Q3 Earnings: Beats Estimates On Knee Procedures Strength, But Cuts Guidance
Zimmer Biomet Holdings Inc (NYSE: ZBH) reported  
Via Benzinga
Weight-Loss Drugs Spooked Medical Device Stocks. Did Investors Overreact?
Makers of devices to treat obesity-related conditions have struggled recently. Analysts say there's more to the story. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For October 20, 2023
Via Benzinga
Earnings Scheduled For November 7, 2023
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter. 
Via Benzinga
Where Zimmer Biomet Holdings Stands With Analysts
Via Benzinga
7 Healthcare Stocks to invest in for a Healthy Future
Considering today's economic uncertainty and market turns, healthcare stocks may be one of the few winning sectors. Here are the winners. 
Via InvestorPlace
Is the Ozempic-Driven DexCom Selloff Overdone?
Has glucose monitor maker DexCom corrected too much on fears of lost sales due to weight loss and diabetes drugs made by Novo Nordisk and Eli Lilly? 
Via MarketBeat
7 High-Growth S&P 500 Stocks to Buy Now
Although industry stalwarts don’t typically offer robust profitability potential, these high-growth S&P 500 stocks might change your tune. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Analyst Ratings for Zimmer Biomet Holdings
Via Benzinga
Peering Into Zimmer Biomet Holdings's Recent Short Interest
Via Benzinga
A Look Into Zimmer Biomet Holdings Inc's Price Over Earnings
Via Benzinga
Analyst Expectations for Zimmer Biomet Holdings's Future
Via Benzinga
3 Undervalued Healthcare Stocks to Watch as Sector Struggles
As the healthcare sector slumps, several major stocks, including Zimmer Biomet, Moderna, and Illumina, appear undervalued in contrast to their intrinsic worth. 
Via MarketBeat
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Dexcom Says It Won't Be The Biggest Loser In The Weight-Loss Battle — And Shares Soar
Dexcom says the popularity of GLP-1 drugs won't hurt its continuous glucose monitors. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For August 28, 2023
Via Benzinga
Cramer Gives Auto Semiconductor Company A Thumbs Down: 'Self-Driving Has Hit A Snag'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Extreme Networks, Inc. (NASDAQ: EXTR) is fine. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS